Lymphodepleting chemotherapy

Phase 3Small molecule

Lymphodepleting chemotherapy is one of 369 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

368

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

LymphomaActive, not recruiting

Metastatic MelanomaActive, not recruiting

Autoimmune DiseaseActive, not recruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Breast CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Multiple MyelomaActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Systemic Lupus ErythematosusPreclinical

Active, not recruiting

LymphomaPhase 2

Active, not recruiting

Metastatic MelanomaPhase 1/Phase 2

Active, not recruiting

Autoimmune DiseasePhase 1

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Renal Cell CarcinomaPhase 1

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Showing 10 of 12 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lymphodepleting chemotherapy

BBeijing Biotech

Phase 3

1 2

Tecentriq

Roche

Preclinical

36 3

Tykerb

GSK

Preclinical

80 4

Adriamycin

GGynecologic Oncology Group

Preclinical

87 5

Avastin

BBio-Thera Solutions

Preclinical

153 6

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 7

Prolia

Amgen

Preclinical

14 8

Gemzar

GGynecologic Oncology Group

Preclinical

22 9

DATROWAY

Daiichi Sankyo

Preclinical

4 10

MS Contin

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Igg4 Related Disease

NCT07061938

Q4 2027

N/ANot yet recruiting

Systemic Lupus Erythematosus

NCT07314567

Q1 2028

Phase 1/2Recruiting

Advanced NSCLC

NCT07467863

Phase 1/2Recruiting

Breast Cancer

NCT07486089

Q2 2028

Phase 1/2Recruiting

Small Cell Lung Cancer

NCT07480213

Phase 1/2Recruiting

Ovarian Cancer

NCT07480954

Clinical

Trials by Indication[1]

Lymphoma2 trials

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

Completed· Novartis logo

Novartis·Phase 2·NCT03610724·34 enrolled

Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas

Active, not recruiting·PPatrick C. Johnson, MD·Phase 2·NCT05583149·28 enrolled

Autoimmune Disease1 trial

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

Active, not recruiting·CCentury Therapeutics, Inc.·Phase 1·NCT06255028·6 enrolled

Breast Cancer1 trial

Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Recruiting·BBeijing Biotech·Phase 1/2·NCT07486089·60 enrolled

Ovarian Cancer1 trial

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

Recruiting·BBeijing Biotech·Phase 1/2·NCT07480954·36 enrolled

Metastatic Melanoma1 trial

Vemurafenib and TIL Therapy for Metastatic Melanoma

Completed·IInge Marie Svane·Phase 1/2·NCT02354690·13 enrolled

11 more indications

IgG4 Related Disease1 trial

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

Recruiting·AAcepodia Biotech, Inc.·Phase 1/2·NCT07061938·30 enrolled

Follicular Lymphoma1 trial

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Active, not recruiting· Novartis logo

Novartis·Phase 3·NCT05888493·109 enrolled

Small Cell Lung Cancer1 trial

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

Recruiting·BBeijing Biotech·Phase 1/2·NCT07480213·60 enrolled

Efficacy and Safety1 trial

Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients

Completed· Novartis logo

Novartis·Phase 2·NCT02445248·115 enrolled

Advanced NSCLC1 trial

Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC

Recruiting·BBeijing Biotech·Phase 1/2·NCT07467863·48 enrolled

Systemic Lupus Erythematosus1 trial

ACE1831 in Adult Subjects With Relapsed/Refractory Systemic Lupus Erythematosus （SLE）

Not yet recruiting·TTongji Hospital·N/A·NCT07314567·22 enrolled

B-cell Malignancies1 trial

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Terminated·CCentury Therapeutics, Inc.·Phase 1·NCT05336409·28 enrolled

Renal Cell Carcinoma1 trial

Phase I Study of Allogeneic Transforming Growth Factor-beta Receptor Type 2 Knockout CD70 CAR NK Cells in Treatment Refractory Clear Cell Renal Cell Carcinoma

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07072234·30 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma

Recruiting·BBeijing Biotech·Phase 1/2·NCT07480928·42 enrolled

Multiple Myeloma1 trial

Phase 1 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

Recruiting·WWashington University School of Medicine·Phase 1·NCT06185751·25 enrolled

Large B-cell Lymphoma1 trial

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT07316010·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Lymphodepleting chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lymphodepleting chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lymphodepleting chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Beijing Biotech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBeijing Biotech

Lymphodepleting chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2027

Q1 2028

Q2 2028

Trials by Indication[1]

Lymphoma2 trials

Autoimmune Disease1 trial

Breast Cancer1 trial

Ovarian Cancer1 trial

Metastatic Melanoma1 trial

IgG4 Related Disease1 trial

Follicular Lymphoma1 trial

Small Cell Lung Cancer1 trial

Efficacy and Safety1 trial

Advanced NSCLC1 trial

Systemic Lupus Erythematosus1 trial

B-cell Malignancies1 trial

Renal Cell Carcinoma1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Multiple Myeloma1 trial

Large B-cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News